Prediabetes & diabetes prevention

Prolonged follow-up of high-risk people treated with teplizumab to prevent progression to type 1 diabetes shows a lasting beneficial effect on beta-cell function, say researchers.

The incidence of diabetes in high- and middle-income countries may at last be stabilizing, or even in decline, say researchers.

Delaying progression from impaired glucose tolerance to type 2 diabetes reduces the risk for micro- and macrovascular complications, shows 24 years of follow-up of the Da Qing trial.

Adults who develop prediabetes when older than 70 years are more likely to regress to normoglycemia or die of other causes than to progress to type 2 diabetes, research shows.

Use of the SGLT2 inhibitor dapagliflozin is associated with a reduced risk for new-onset type 2 diabetes in high-risk individuals with heart failure and reduced ejection fraction, suggests an exploratory analysis of data from the DAPA-HF trial.

A randomized trial indicates that testosterone treatment among men with prediabetes or newly diagnosed type 2 diabetes significantly reduces the risk for them having type 2 diabetes 2 years later.

The SGLT2 inhibitor empagliflozin may reverse adverse left ventricular remodeling in people who have heart failure with reduced ejection fraction and type 2 diabetes or prediabetes, shows a randomized trial.

Lifestyle intervention significantly reduces the risk for type 2 diabetes in people who have prediabetes based on fasting plasma glucose or glycated hemoglobin measurements, show findings from a randomized trial.

The excess risk for myocardial infarction associated with having diabetes may be greater in women than men, despite men having a higher frequency of events overall, shows research from the UK Biobank.

Prediabetes is associated with an elevated risk for all-cause mortality and cardiovascular events, both in the general population and in patients with atherosclerotic cardiovascular disease, shows an updated meta-analysis published in The BMJ.

Focusing efforts on convincing people to return after the first session of the US National Diabetes Prevention Program lifestyle change program, and after the transition to less frequent sessions, may help to optimize program retention, say researchers.

The increased risk for prediabetes among ethnic minorities compared with White people is less pronounced in neighborhoods with high walkability, shows a Canadian study.

Several therapies aimed at slowing the progression of early type 1 diabetes show promise in research presented at the virtual 80th ADA Scientific Sessions.

Among the latest findings from the DPP Outcomes Study is that long-term use of metformin does not affect the risk for cancer.